Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GNTANASDAQ:IGMSNASDAQ:IMRXOTCMKTS:LTUS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGNTAGenenta Science$3.07-1.2%$4.07$2.79▼$7.28$56.88M0.7315,158 shs6,574 shsIGMSIGM Biosciences$1.17$1.25$0.92▼$22.50$69.94M0.52305,614 shs241,889 shsIMRXImmuneering$2.56-7.6%$1.62$1.00▼$3.83$99.68M0.012.51 million shs4.70 million shsLTUSLotus Pharmaceuticals$0.01$0.01$0.00▼$0.01$19.04M-2.4851,355 shsN/A7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGNTAGenenta Science-1.16%-20.67%-26.81%-25.93%-4.68%IGMSIGM Biosciences0.00%-3.31%-0.85%-1.68%-83.84%IMRXImmuneering-7.58%+34.74%+72.97%+42.22%+72.97%LTUSLotus Pharmaceuticals0.00%+4.35%+63.64%-7.69%+118.18%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGNTAGenenta Science2.9726 of 5 stars3.55.00.00.02.81.70.0IGMSIGM Biosciences4.0197 of 5 stars3.04.00.04.60.03.30.6IMRXImmuneering3.3028 of 5 stars3.32.00.00.03.15.00.6LTUSLotus PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGNTAGenenta Science 3.00Buy$25.00713.27% UpsideIGMSIGM Biosciences 1.90Reduce$5.50370.09% UpsideIMRXImmuneering 2.60Moderate Buy$13.25417.58% UpsideLTUSLotus Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest LTUS, IGMS, GNTA, and IMRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/18/2025IMRXImmuneeringMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$8.00 ➝ $10.006/18/2025IMRXImmuneeringChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.006/18/2025IMRXImmuneeringNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.006/5/2025IMRXImmuneeringNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.005/7/2025IMRXImmuneeringOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$25.00 ➝ $21.005/6/2025IMRXImmuneeringChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.00 ➝ $13.004/10/2025IMRXImmuneeringNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.003/24/2025IMRXImmuneeringChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.00 ➝ $13.003/21/2025IMRXImmuneeringNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.00(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGNTAGenenta ScienceN/AN/AN/AN/A$0.74 per shareN/AIGMSIGM Biosciences$2.68M26.10N/AN/A$0.82 per share1.43IMRXImmuneering$320K287.92N/AN/A$1.33 per share1.92LTUSLotus PharmaceuticalsN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGNTAGenenta Science-$9.64MN/A0.00N/AN/AN/AN/AN/AN/AIGMSIGM Biosciences-$195.79M-$3.27N/AN/AN/A-7,417.79%-317.97%-71.43%8/13/2025 (Estimated)IMRXImmuneering-$61.04M-$1.96N/AN/AN/AN/A-119.22%-99.22%8/5/2025 (Estimated)LTUSLotus Pharmaceuticals$110KN/A0.00∞N/AN/AN/AN/AN/ALatest LTUS, IGMS, GNTA, and IMRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025IGMSIGM Biosciences-$0.41-$0.86-$0.45-$0.86$4.25 million$0.50 million5/5/2025Q1 2025IMRXImmuneering-$0.41-$0.42-$0.01-$0.42N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGNTAGenenta ScienceN/AN/AN/AN/AN/AIGMSIGM BiosciencesN/AN/AN/AN/AN/AIMRXImmuneeringN/AN/AN/AN/AN/ALTUSLotus PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGNTAGenenta ScienceN/A6.896.89IGMSIGM BiosciencesN/A5.715.71IMRXImmuneeringN/A7.487.48LTUSLotus PharmaceuticalsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGNTAGenenta Science15.13%IGMSIGM Biosciences42.79%IMRXImmuneering67.65%LTUSLotus PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipGNTAGenenta Science28.99%IGMSIGM Biosciences57.00%IMRXImmuneering22.90%LTUSLotus PharmaceuticalsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGNTAGenenta Science718.29 million12.99 millionNot OptionableIGMSIGM Biosciences19059.78 million25.70 millionOptionableIMRXImmuneering6035.99 million27.75 millionNot OptionableLTUSLotus Pharmaceuticals2302.64 billionN/ANot OptionableLTUS, IGMS, GNTA, and IMRX HeadlinesRecent News About These CompaniesLotus Therapeutics Appoints Leslie Felix as Chief Growth OfficerJune 4, 2025 | finance.yahoo.comSperanza Therapeutics Launches New Division to Help Pharma Manufacturers Adapt to Market ShiftsApril 23, 2025 | finance.yahoo.comLotus Pharmaceutical becomes strategic partner for…February 5, 2025 | pharmiweb.comTaiwan’s pharma firm Lotus acquires edema medicine rights in Vietnam from SanofiJanuary 9, 2025 | theinvestor.vnlotus exchangeDecember 28, 2024 | everythingexperiential.businessworld.inBoryung, Lotus Pharma signs CDMO deal on anticancer injectionDecember 12, 2024 | kedglobal.comLotus Pharmaceuticals Inc Price / BookNovember 20, 2024 | investing.comLotus Bakeries: When Growth Potential Meets Pricey ExpectationsNovember 13, 2024 | seekingalpha.comUSA Knotless Surgical Sutures Market Expected to Reach USD 258.7 Million by 2033 at a 3.6% of CAGRNovember 1, 2024 | fmiblog.com20 Shows Like ‘Black Mirror’ That’ll Definitely Mess with Your HeadNovember 1, 2024 | yahoo.comLotus Bakeries: A Sweet Business With Exponential GrowthOctober 27, 2024 | seekingalpha.comA Forbidden Lotus Elise Rival Is for Sale in the U.S. Right NowOctober 24, 2024 | msn.comNatasha Rothwell Opens Up About 'The White Lotus' Season 3, 'How to Die Alone' & MoreOctober 23, 2024 | msn.comLotus Resources Plans Equity Raise for Uranium ProjectOctober 22, 2024 | markets.businessinsider.comLotus of Love Cancer IncOctober 20, 2024 | msn.comThis 90s-Era GM-Lotus Mashup Was The Ultimate Sleeper SedanOctober 19, 2024 | topspeed.comWhy Romantics Love the Lotus Sex Position, According to a SexologistOctober 9, 2024 | popsugar.comTopic: @lotusOctober 9, 2024 | arstechnica.com2025 Lotus Emira Gets 400-HP Turbo SE VersionOctober 9, 2024 | autoevolution.comSee CEO plans as Lotus Bank opens new branch, makes promisesOctober 8, 2024 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLTUS, IGMS, GNTA, and IMRX Company DescriptionsGenenta Science NASDAQ:GNTA$3.07 -0.04 (-1.16%) Closing price 06/20/2025 03:48 PM EasternExtended Trading$3.00 -0.07 (-2.37%) As of 06/20/2025 05:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.IGM Biosciences NASDAQ:IGMS$1.17 0.00 (0.00%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$1.17 0.00 (0.00%) As of 06/20/2025 04:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.Immuneering NASDAQ:IMRX$2.56 -0.21 (-7.58%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$2.49 -0.07 (-2.77%) As of 06/20/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.Lotus Pharmaceuticals OTCMKTS:LTUS$0.0072 0.00 (0.00%) As of 06/18/2025Lotus Pharmaceuticals, Inc. does not have significant operations. Previously, it was engaged in the development, manufacture, and sale of pharmaceuticals in the People's Republic of China. The company is based in Nashville, Tennessee. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Overheated Market? Analysts Watch These Red Flags Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
